H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.

Abstract

Methylation at histone 3, lysine 36 (H3K36) is a conserved epigenetic mark regulating gene transcription, alternative splicing and DNA repair. Genes encoding H3K36 methyltransferases (KMTases) are commonly overexpressed, mutated or involved in chromosomal translocations in cancer. Molecular biology studies have demonstrated that H3K36 KMTases regulate… (More)
DOI: 10.4155/fmc-2016-0071

Topics

Cite this paper

@article{Rogawski2016H3K36MA, title={H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.}, author={David S. Rogawski and J. Grembecka and Tomasz Cierpicki}, journal={Future medicinal chemistry}, year={2016}, volume={8 13}, pages={1589-607} }